Long term biventricular support with Berlin Heart Excor in a Septuagenarian with giant-cell myocarditis

Christian Bireta¹*, Theodor Tirilomis¹, Marius Grossmann¹, Bernhard Unsöld², Rolf Wachter², Thorsten Perl³, Ahmad Fawad Jebran¹, Friedrich Albert Schoendube¹ and Aron Frederik Popov¹

Abstract

Giant-cell myocarditis (GCM) is known as a rare, rapidly progressive, and frequently fatal myocardial disease in young and middle-aged adults. We report about a 76 year old male patient who underwent implantation with a biventricular Berlin Heart Excor system at the age of 74 due to acute biventricular heart failure caused by giant-cell myocarditis. The implantation was without any surgical problems; however, a difficulty was the immunosuppressive therapy after implantation. Meanwhile the patient is 76 years old and lives with circulatory support for about 3 years without major adverse events. Also, in terms of mobility in old age there are no major limitations. It seems that in even selected elderly patients an implantation of a long term support with the biventricular Berlin Heart Excor is a useful therapeutic option with an acceptable outcome.

Background

Giant-cell myocarditis (GCM) is known as a rare, rapidly progressive, and frequently fatal myocardial disease in young and middle-aged adults. However, few cases have been reported on GCM in older patients. The paucity of reported cases on the elderly may reflect less frequent diagnosis or more or less fulminant course of disease in this population. Infection, autoimmune processes, and genetics have all been implicated in the pathogenesis of this disease, but the etiology is likely to be a complex multifactorial process. It is attributed to a T lymphocyte-mediated inflammation of the heart muscle and associates with systemic autoimmune diseases in 20% of cases [1,2]. The most common early manifestations are heart failure, ventricular arrhythmias, and atioventricular block, but GCM may also appear as an acute myocardial infarction and rarely presents as an unexpected sudden cardiac death. Due to this unspecific clinical presentation of the patients, which may also be caused by other heart disease, the diagnosis of GCM fully depends on microscopy of the heart muscle with a sensitivity of 80% to 85% [1,2]. The histological hallmark of GCM is a multifocal inflammatory infiltrate manifested by many multinucleated giant cells and by extensive myocardial cell necrosis in the absence of granuloma formation [3]. Because of possible life threatening complications associated with GCM and the potential for benefit from treatment, early biopsy is recommended. An early diagnosis of GCM is crucial. Also, apart from standard heart failure therapy and physical rest a tailored immunosuppressive treatment may significantly alter the clinical course of the patients. The prognosis of patients with GCM is poor, and the probability of death or transplantation at 1 year from onset of symptoms is high [1,2]. Even after transplantation, there is a 20-25% GCM recurrence in the transplanted heart [4].

Case presentation

A 74 year-old man was transferred to our institution with biventricular heart failure and suspected myocarditis. One week earlier, he was admitted to a local hospital due to decreased exercise tolerance and a rapidly worsening shortness of breath. Three weeks before, he had flu-like syndrome. Due to coronary heart disease the patient had undergone a coronary artery bypass grafting 20 years

* Correspondence: Christian.Bireta@med.uni-goettingen.de
¹Department of Thoracic and Cardiovascular Surgery, University of Goettingen, Goettingen, Robert-Koch-Strasse 40, 37075 Goettingen, Germany
Full list of author information is available at the end of the article

© 2015 Bireta et al; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Giant-cell myocarditis is known as a rare, rapidly progressive, and frequently fatal myocardial disease in young and middle-aged adults. However, few cases have been reported in older patients. GCM has multiple causes and the etiology is likely to be a complex multifactorial process which is attributed to T lymphocyte-mediated inflammation of myocardium. The prognosis of patients with GCM is poor and the probability of death or transplantation is high. Apart from standard heart failure therapy a tailored immunosuppressive treatment may significantly alter the clinical course of the patients [1,2]. A recent work from Kandolin et al. shows that combined immunosuppression may lead to a partial remission characterized by freedom from severe heart failure and better estimated transplant-free survival [5].

Mechanical circulatory support with intra-aortic balloon pump, ECMO, and ventricular assist device (VAD) therapy have all been used in GCM patients as bridge to transplantation or occasional recovery [1,6]. As in our case transplantation was not possible due to the high age of the patient. The only therapeutic option was implantation of a BIVAD. Critical circulatory status, previous cardiac operations, older age and associated multimorbidity are the key determinants rendering the conditions of permanent mechanical circulatory support (MCS) in patients of advanced age and are associated with a high postoperative mortality in this cohort [7]. Optimal patient selection and timing of MCS implantation are closely related to ethical issues. There is still a question based on which criteria can we predict the clinical course and when are we allowed to decide about the restriction of access to MCS in severely ill patients with limited prognosis. In our opinion, as well as by others, because of the high early mortality, the inclusion of patients with the combination of advanced age and profound ECMO implantation and all measurable values (e.g. creatinine, urea liver enzymes) were within normal range. He did not require dialysis and had no need for re-exploration for bleeding. And thirdly, he was neurologically alert responsive straight after ECMO implantation and expressed the wish for a BIVAD implantation after diagnosis assurance. We choose the Berlin Heart Excor system for some reasons. There is a huge experience with this system worldwide even in elderly patients. Also, long-term surviving patients with the Berlin Heart Excor required exceptionally few hospital readmissions resulting in a long out-of-hospital VAD support time. And finally the EXCOR® Adult is intended for use in acute or chronic ventricular failure refractory to optimal medical and interventional therapy especially for biventricular heart failure. Our patient is meanwhile 76 years old and lives with circulatory support for about 3 years with no major problems and without major adverse events.

Discussion

Giant-cell myocarditis is known as a rare, rapidly progressive, and frequently fatal myocardial disease in young and middle-aged adults. However, few cases have been reported in older patients. GCM has multiple limitations. Our patient is meanwhile 76 years old and lives with circulatory support for about 3 years with no major adverse events.

Conclusions

Even in selected elderly patients an implantation and long term support with the biventricular Berlin Heart
Excor may be useful as a therapeutic option with an acceptable outcome.

**Consent**
Written informed consent was obtained from the patient for publication of this Case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

**Abbreviations**
GCM: Giant-cell myocarditis; ECG: Electrocardiography; bpm: Beats per minute; LV: Left ventricular; BIVAD: Biventricular ventricular assist device; ECMO: Extracorporeal membrane oxygenation; MCS: Mechanical circulatory support.

**Competing interests**
The authors declare that they have no competing interests.

**Authors’ contributions**
CB, AFP and AFJ drafted the manuscript. MG, TT, BU, RW and TP analyzed and interpreted the patient data. AFP conceptualized the manuscript. FAS was involved in the crucial revisions of manuscript. All authors read and approved the final manuscript.

**Author details**
1Department of Thoracic and Cardiovascular Surgery, University of Goettingen, Goettingen, Robert-Koch-Strasse 40, 37075 Goettingen, Germany.
2Department of Cardiology and Pneumology, University of Goettingen, Robert-Koch-Strasse, 40, 37075 Goettingen, Germany.
3Department of Anesthesiology, Emergency and Intensive Care Medicine, University of Goettingen, Robert-Koch-Strasse 40, 37075 Goettingen, Germany.

**Received: 2 November 2014 Accepted: 18 January 2015**

**Published online: 31 January 2015**

**References**
1. Blauwet LA, Cooper LT. Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Fail Rev. 2013;18(6):733–46.
2. Cooper Jr LT, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis - natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med. 1997;336(26):1860–6.
3. Davies MJ, Pomerance A, Teare RD. Idiopathic giant cell myocarditis – a distinctive clinic-pathological entity. Br Heart J. 1975;37(2):192–5.
4. Scott RL, Ratliff NB, Starling RC, Young JB. Recurrence of giant cell myocarditis in cardiac allograft. J Heart Lung Transplant. 2001;20(3):375–80.
5. Kandolin R, Lehtonen J, Salmenkivi K, Räisänen-Sokolowski A, Lommi J, Kupari M. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail. 2013;6(1):15–22.
6. Popov AF, Hosseini MT, Zych B, Mohite P, Hards R, Krueger H, et al. Clinical experience with HeartWare left ventricular assist device in patients with end-stage heart failure. Ann Thorac Surg. 2012;93(3):810–5.
7. Jurmann MJ, Weng Y, Drews T, Pasic M, Henning E, Hetzer R. Permanent mechanical circulatory support in patients of advanced age. Eur J Cardiothorac Surg. 2004;25(4):610–8.